Apotex Sues to Clear Tradjenta Copy of Boehringer Patent Claims

Apotex Inc. asked a federal court in Delaware for a judgment that its proposed generic version of Tradjenta doesn’t infringe three Boehringer Ingelheim International GmbH patents for the diabetes drug.

Apotex filed the declaratory-judgment complaint under seal Wednesday in the US District Court for the District of Delaware “because it contains Apotex’s highly-sensitive manufacturing information,” according to its concurrent request seeking permission to do so.

The documents were docketed Thursday, when Judge Gregory B. Williams, ruling from the bench, also granted the motion. He ordered Apotex to file a redacted version of the complaint by July 6.

Apotex said excerpts ...